Post-ASH 2025 AML Highlights

Featuring presentations & discussions on selected AML abstracts from the 67^th ASH Annual Meeting and Exposition

Thursday 22 January | 09:00 – 11:00 CST/ 15:00 – 17:00 GMT/ 16:00 – 18:00 CET

Chair: Naval Daver | Moderators: Courtney DiNardo and Charles Craddock

Register Now

Preliminary Agenda:

Welcome and introductions 

Session 1: Novel approaches to conditioning in AML 

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial (ABSTRACT ID abs25-11238; ABSTRACT ID 378) | Speaker: Uday Popat

Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact COSI trial (ABSTRACT ID abs25-2504; ABSTRACT ID 110) | Speaker: Charles Craddock

Panel Discussion

Session 2: Latest with venetoclax-based therapy in newly-diagnosed AML

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (ABSTRACT ID abs25-14054; ABSTRACT ID 45) | Speaker: Roberta Santos Azevedo 

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study (ABSTRACT ID abs25-2677; ABSTRACT ID 654) | Speaker: Jessica Altman

Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML): A multicenter, prospective, randomized phase II trial (ABSTRACT ID abs25-9289; ABSTRACT ID 650) | Speaker: TBC

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA (ABSTRACT ID abs25-8754; ABSTRACT ID 995) | Speaker: Fieke Hoff

Results from paradigm – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia (ABSTRACT ID abs25-8236; ABSTRACT ID 6) | Speaker: Amir Fathi

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study (ABSTRACT ID abs25-2270; ABSTRACT ID 453) | Speaker: Curtis Lachowiez 

Panel Discussion

Session 3: Advances with I-O therapies in AML

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia (ABSTRACT ID abs25-2524; ABSTRACT ID 651) | Speaker: David Sallman

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action (ABSTRACT ID abs25-2711; ABSTRACT ID 5921) | Speaker: TBC

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS) (ABSTRACT ID abs25-2075; ABSTRACT ID 768) | Speaker: Maher Abdul-Hay

Panel Discussion

Session 4: Recent progress with menin inhibitors in AML 

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study (ABSTRACT ID abs25-1793; ABSTRACT ID 1001) | Speaker: TBC

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007 (ABSTRACT ID abs25-3889; ABSTRACT ID 766) | Speaker: Amer Zeidan

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007 (ABSTRACT ID abs25-3910; ABSTRACT ID 764) | Speaker: Eunice Wang

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy (ABSTRACT ID abs25-7725; ABSTRACT ID 3429) | Speaker: TBC

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia (ABSTRACT ID abs25-2036; ABSTRACT ID 763) | Speaker: Naval Daver

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia (ABSTRACT ID abs25-2037; ABSTRACT ID 765) | Speaker: Justin Watts

Panel Discussion

Conclusions and meeting close